ISALY SAMUEL D Form SC 13G/A February 18, 2004

> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G/A Under the Securities Exchange Act of 1934 Amendment No. 1 Atrix Laboratories, Inc. (Name of Issuer)

> Common Stock (Title of Class of Securities)

> > 04962L101 (CUSIP Number)

December 31, 2003

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [x] Rule 13d-1(b)
- [ ] Rule 13d-1(c)
- [ ] Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

#### CUSIP No. 04962L101

Names of Reporting Persons.

 I.R.S. Identification Nos. of above persons (entities only).

OrbiMed Advisors LLC

2. Check the Appropriate Box if a Member Of a Group (See Instructions)

|                    |     | [ ] (a)<br>[ ] (b)  |
|--------------------|-----|---|
|                    | 3.  | SEC Use Only  |
|                    | 4.  | Citizenship or Place of Organization  |
|                    |     | Delaware  |
| Number             | 5.  | Sole Voting Power: 0  |
| Shares             |     | 6. Shared Voting Power: 1,974,300   |
| Benefic<br>Owned b | ру  | 7. Sole Dispositive Power: 0  |
| Each Re<br>Person  | -   | 8. Shared Dispositive Power: 1,974,300  |
|                    | 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person 1,974,300                      |
|                    | 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares<br>(See Instructions)      |
|                    | 11. | Percent of Class Represented by Amount in Row (9) 9.20%                                     |
|                    | 12. | Type of Reporting Person (See Instructions) IA  |
|                    |     |   |
|                    |     |   |
|                    |     |   |
|                    |     | CUSIP No. 04962L101   |
|                    | 1.  | Names of Reporting Persons.<br>I.R.S. Identification Nos. of above persons (entities only). |
|                    |     | OrbiMed Capital LLC   |
|                    | 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                         |
|                    |     | [ ] (a)<br>[ ] (b)  |
|                    | 3.  | SEC Use Only  |
|                    | 4.  | Citizenship or Place of Organization  |

Delaware

5.Sole Voting Power: 0Number ofShares6.Shared Voting Power: 1,974,300BeneficiallyOwned by7.Sole Dispositive Power: 0Each ReportingPerson With8.Shared Dispositive Power: 1,974,300

9. Aggregate Amount Beneficially Owned by Each Reporting Person

1,974,300

- Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 9.20%
- 12. Type of Reporting Person (See Instructions) IA

CUSIP No. 04962L101

Names of Reporting Persons.
 I.R.S. Identification Nos. of above persons (entities only).

Samuel D. Isaly

2. Check the Appropriate Box if a Member of a Group (See Instructions)

[ ] (a) [ ] (b)

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

United States

|             | 5.       | Sole Voting Power: 0                                      |
|-------------|----------|---|
| Number of   |          |   |
| Shares      | 6.       | Shared Voting Power: 1,974,300                            |
| Beneficiall | У        |   |
| Owned by    | 7.       | Sole Dispositive Power: 0                                 |
| Each Report | ing      |   |
| Person With | 8.       | Shared Dispositive Power: 1,974,300                       |
|             |          |   |
| 9.          | Aggrega  | te Amount Beneficially Owned by Each Reporting Person:    |
|             | 1,974,3  | 00  |
|             |          |   |
| 10.         | Check i  | f the Aggregate Amount in Row (9) Excludes Certain Shares |
|             | (See In: | structions)   |
|             |          |   |
| 11.         | Percent  | of Class Represented by Amount in Row (9) 9.20 %          |
|             |          |   |

12. Type of Reporting Person (See Instructions) HC

Item 1. (a) Issuer: Atrix Laboratories, Inc.

 Address: 2579 Midpoint Drive

Fort Collins, Colorado 80525

- Item 2. (a) Name of Person Filing: OrbiMed Advisors LLC OrbiMed Capital LLC Samuel D. Isaly
  - (b) Address of Principal Business Offices:

767 Third Avenue, 30th Floor New York, New York 10017

- (c) Citizenship: Please refer to Item 4 on each cover sheet for each filing person
- (d) Title of Class of Securities Common stock

(e) CUSIP Number: 04962L101

Item 3. OrbiMed Advisors Inc. and OrbiMed Advisors LLC are investment advisors in accordance withss.240.13d-1(b)(1)(ii)(E). Samuel D. Isaly is a control person in accordance with ss.240.13d-1(b)(1)(ii)(G).

Item 4. Ownership

Please see Items 5 - 9 and 11 for each cover sheet for each filing separately  $\$ 

Item 5. Ownership of Five Percent or Less of a Class Not Applicable

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Reporting persons are holding 9.20% of the securities on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from or proceeds from sole of, such securities.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not Applicable

Item 8. Identification and Classification of Members of the Group

Not Applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the

securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 17, 2004

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: President

OrbiMed Capital LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

By: /s/ Samuel D. Isaly ------Name: Samuel D. Isaly

EX-1.1 OTHERDOC 2 0002.txt

JOINT FILING AGREEMENT

Exhibit 1.1

#### JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on this Schedule 13G/A, dated February 17, 2004, (the "Schedule 13G/A"), with respect to the Common Stock, par value \$.001 per share, of Atrix Laboratories, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to this Schedule 13G/A. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G/A, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of

counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 17 day of February 2004.

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: President

OrbiMed Capital LLC

By: /s/ Samuel D. Isaly ------Name: Samuel D. Isaly

Title: Managing Member

By: /s/ Samuel D. Isaly Name: Samuel D. Isaly

EX-2.1 OTHERDOC Statement of Control Person

Exhibit 2.1

Statement of Control Person

The Statement on this Schedule 13G/A dated February 17, 2004 with respect to the common stock 0.01 par value per share of Atrix Laboratories, Inc. is filed by Samuel D. Isaly in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k), respectively, as a control person (HC) of OrbiMed Advisors LLC and OrbiMed Capital LLC.

OrbiMed Advisors LLC and OrbiMed Capital LLC file this statement on Schedule 13G/A in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k), respectively, as investment advisors (IA).

guidance provided to analysts and rating agencies.

2. Review with Trust management and the independent auditors the matters that auditing professional standards require to be communicated to the Audit Committee, including, but not limited to, the matters required to be discussed by Statement on Auditing Standards No. 61, including:

the independent auditors' judgments about the quality, and not just the acceptability, of the Trust's accounting principles as applied in its financial reporting;

the process used by Trust management in formulating estimates and the independent auditors' conclusions regarding the reasonableness of those estimates;

all significant adjustments arising from the audit, whether or not recorded by the Trust;

when the independent auditors are aware that Trust management has consulted with other accountants about significant accounting and auditing matters, the independent auditors' views about the subject of the consultation;

any disagreements with Trust management regarding accounting or reporting matters;

any difficulties encountered in the course of the audit, including any restrictions on the scope of the independent auditors' activities or on access to requested information; and

A-3

significant deficiencies in the design or operation of internal controls.

3. The independent auditors shall report, within 90 days prior to the filing of the Trust's annual financial statements with the SEC, to the Audit Committee:

(a) all critical accounting policies and practices to be used;

(b) all alternative treatments of financial information within GAAP for policies and practices related to material items that have been discussed with Trust management, the ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent auditor;

(c) other material written communications between the independent auditors and Trust management including, but not limited to, any management letter or schedule of unadjusted differences; and

(d) all non-audit services provided to an entity in the "investment company complex" as defined in paragraph (f)(14) of Rule 2-01 of Regulation S-X that were not pre-approved by the Audit Committee.

4. Review, annually, with Trust management and the independent auditors, the Trust's "disclosure controls and procedures" and the Trust's "internal control over financial reporting" as defined in Rule 30a-3(c) and (d) under the Investment Company Act of 1940.

5. Review with Trust management and the independent auditors a report by Trust management covering any Form N-CSR and Form N-Q filed, and any required certification of such filing, along with the results of Trust management's most recent evaluation of the Trust's "disclosure controls and procedures" and "internal control over financial reporting."

#### E. Process Improvements

Review with the independent auditors and Trust management significant changes or improvements in accounting and auditing processes that have been implemented.

#### F. Legal and Compliance

1. Review any legal or regulatory matters that arise that could have a material impact on the Trust's financial statements.

2. Review policies and procedures with respect to financial statement risk assessment and risk management, including the steps Trust management has taken to monitor and control such risk exposures.

3. Establish clear hiring policies for the Trust with respect to employees or former employees of the independent auditors.

#### G. Other Responsibilities

1. Review, annually, the performance of the Audit Committee.

2. If the Trust is a closed-end investment company, prepare a report of the Audit Committee as required to be included in the annual proxy statement.

3. Investigate any other matter brought to its attention within the scope of its duties, and have the authority in its discretion to retain legal, accounting or other experts or consultants to advise the Audit Committee, at the expense of the Trust, if, in the Committee's judgment, that is appropriate.

4. Perform any other activities consistent with this Charter, the Trust's Charter, By-Laws and governing law, as the Audit Committee or the Board deems necessary or appropriate.

5. Maintain minutes of Committee meetings; report its significant activities to the Board; and make such recommendations to the Board as the Audit Committee may deem necessary or appropriate.

### V. FUNDING

The Audit Committee shall receive appropriate funding, as determined by the Audit Committee, for payment of (i) compensation to the independent auditors for approved audit or non-audit services for the Trust; (ii) compensation to any legal, accounting or other experts or consultants retained by the Audit Committee pursuant to Section IV.G.3 above and (iii) ordinary administrative expenses of the Audit Committee that are necessary or appropriate in carrying out its duties.

#### **BACKGROUND AND DEFINITIONS**

#### FOR

#### AUDIT COMMITTEE CHARTER

The following is supplemental information regarding the Audit Committee Charter designed to provide the Audit Committee background information and definitions to assist the Committee in fulfilling its responsibilities under the Charter.

#### I. COMPOSITION

An "audit committee financial expert" of a company is defined as a person who has all of the following attributes: (1) an understanding of generally accepted accounting principles ("GAAP") and financial statements; (2) the ability to assess the general application of GAAP in connection with the accounting for estimates, accruals and reserves; (3) experience preparing, auditing, analyzing or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the company's financial statements, or experience actively supervising one or more persons engaged in such activities; (4) an understanding of internal controls and procedures for financial reporting; and (5) an understanding of audit committee functions. An audit committee financial expert must have acquired such attributes through any one or more of the following: (1) education and experience as a principal financial officer, principal accounting officer, controller, public accountant or auditor or experience in one or more positions that involve the performance of similar functions (or active supervision of such persons); or (2) experience overseeing or assessing the performance of companies or public accountants with respect to the preparation, auditing or evaluation of financial statements; or (3) other relevant experience.

If the Trust is listed on the New York Stock Exchange, at least one member of the Audit Committee must have accounting or related financial management expertise, as the Board interprets such qualification in its business judgment.

#### **II. RESPONSIBILITIES AND DUTIES**

#### A. Pre-Approval Not Required

Under Section 10A(h)(i)(1)(B) of the Securities Exchange Act of 1934 and Rule 2-01 under Regulation S-X (Section (c)(7)), pre-approval of non-audit services for the Trust pursuant to Section IV.C. 2 is not required, if:

1. the aggregate amount of all non-audit services provided to the Trust is no more than 5% of the total fees paid by the Trust to the independent auditors during the fiscal year in which the non-audit services are provided;

2. the services were not recognized by Trust management at the time of the engagement as non-audit services; and

3. such services are promptly brought to the attention of the Audit Committee by Trust management and the Audit Committee approves them (which may be by delegation) prior to the completion of the audit.

Under Section 10A(h)(i)(1)(B) of the Securities Exchange Act of 1934 and Rule 2-01 under Regulation S-X (Section (c)(7)), pre-approval of non-audit services for the Adviser (or any affiliate of the Adviser providing ongoing services to the Trust) pursuant to Section IV.C.3 is not required, if:

1. the aggregate amount of all non-audit services provided is no more than 5% of the total fees paid to the Trust's independent auditors by the Trust, the Adviser and any "control affiliate" of the Adviser providing ongoing services to the Trust during the fiscal year in which the non-audit services are provided;

2. the services were not recognized by Trust management at the time of the engagement as non-audit services; and

3. such services are promptly brought to the attention of the Audit Committee by Trust management and the Audit Committee approves them (which may be by delegation) prior to the completion of the audit.

#### B. Control Affiliate

As used in Section IV.C.3, "control affiliate" means any entity controlling, controlled by, or under common control with the Adviser.

#### C. Prohibited Non-Audit Services

Under Section 10A(g) of the Securities Exchange Act of 1934 and Rule 2-01 under Regulation S-X (Section (c)(4)), an auditor is not independent if, at any point during the audit and professional engagement period, the auditor provides certain non-audit services to an audit client. As referred to in Section IV.C.2, these prohibited non-audit services would include:

- 1. bookkeeping or other services related to the accounting records or financial statements of the Trust;
- 2. financial information systems design and implementation;
- 3. appraisal or valuation services, fairness opinions, or contribution-in-kind reports;
- 4. actuarial services;
- 5. internal audit outsourcing services;
- 6. management functions or human resources;
- 7. broker or dealer, investment adviser, or investment banking services;
- 8. legal services and expert services unrelated to the audit; and
- 9. any other services that the Public Company Accounting Oversight Board determines are impermissible.

#### D. Other Definitions

"Investment company complex" includes: (1) an investment company and its investment adviser or sponsor; (2) any entity controlled by or controlling an investment adviser or sponsor in (1) above, or any entity under common control with any investment adviser or sponsor in (1) above if the entity: (A) is an investment adviser or sponsor or (B) is engaged in the business of providing administrative, custodian, underwriter, or transfer agent services to any investment company, investment adviser, or sponsor; and (3) an investment company or entity that would be an investment company but for the exclusions provided by Section 3(c) of the 1940 Act that has an investment adviser or sponsor included in (1) and (2) above. Investment adviser does not include a subadviser whose role is primarily portfolio management and is subcontracted with or overseen by another investment adviser. Sponsor is an entity that establishes a unit investment trust.

"Disclosure controls and procedures" means controls and other procedures of a registered management investment company that are designed to ensure that information required to be disclosed by the investment company on Form N-CSR and Form N-Q is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an investment company in the reports that it files or submits on Form N-CSR and Form N-Q is accumulated and communicated to the investment company's management, including its principal executive officer or officers and principal financial officer or officers, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

"Internal control over financial reporting" is a process designed by, or under the supervision of, the Trust's principal executive and principal financial officers, or persons performing similar functions, and effected by the Trust's Board, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

1. Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Trust;

2. Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures of the Trust are being made only in accordance with authorization of management and directors of the

3. Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Trust's assets that could have a material effect on the financial statements.

The report to be prepared by the Audit committee to be included in the annual proxy statement is governed by Item 306 of Regulation S-K, which requires each proxy statement relating to a shareholder meeting at which directors are to be elected to include a report, followed by the name of each Audit Committee member, stating whether: (1) the Committee has reviewed and discussed the audited financial statements with management, (2) the Committee has discussed with the independent auditors the matters required to be discussed by SAS 61, (3) the Committee has received the written disclosures and the letter from the independent auditors required by Independence Standards Board Standard No. 1, and has discussed with the independence, and (4) based on the review and discussions referred to in paragraphs (1) through (3), the Audit Committee recommended to the Board that the audited financial statements be included in the Trust's annual report to shareholders required by Section 30(e) of the Investment Company Act of 1940 and Rule 30d-1 thereunder.

A-7

#### Appendix A

#### Funds That Have Approved This

#### Audit Committee Charter

#### Fund

Dreman/Claymore Dividend & Income Fund

Fiduciary/Claymore MLP Opportunity Income Fund

Fiduciary/Claymore Dynamic Equity Fund

Madison/Claymore Covered Call Fund

Old Mutual/Claymore Long-Short Fund

TS&W/Claymore Tax-Advantaged Balanced Fund

Claymore/Guggenheim Strategic Opportunities Fund

Claymore Exchange-Traded Fund Trust

Claymore Exchange-Traded Fund Trust 2

A-8

#### EXHIBIT B

#### CLAYMORE FUNDS

#### Nominating and Governance Committee Charter

#### **Purposes and Organization**

The purpose of Nominating and Governance Committee (the "Committee") of the Board of Trustees (the "Board") of each of the registered investment companies listed in Appendix A hereto (the "Trust(s)") is to review matters pertaining to the composition, committees, and operations of the Board. Members of the Committee may not be "interested persons" of the Trust, as such term is defined in the Investment Company Act of 1940, as amended ("Interested Persons").<sup>1</sup> The Committee shall have the following duties and powers:

(1) To evaluate and recommend all candidates for election or appointment as members of the Board and recommend the appointment of members and chairs of each Board Committee.

(2) To review policy matters affecting the operation of the Board and Board committees and make such recommendations to the Board as deemed appropriate by the Committee.

(3) To evaluate periodically the effectiveness of the Board and Board Committees and make such recommendations to the Board as deemed appropriate by the Committee.

(4) To oversee the contract review process, including the review of the Trust's investment advisory agreements and contracts with other affiliated service providers.

The Committee shall receive appropriate funding as determined by the Committee to carry out its responsibilities and shall have the authority to retain experts, consultants or legal counsel as the Committee deems appropriate.

The Committee shall meet annually (or more frequently, if needed) and be empowered to hold special meetings, as circumstances require. Any action of the Committee shall be taken by the affirmative vote of a majority of the members. Any action of the Committee may be taken without a meeting if at least a majority of the members of the Committee consent thereto in writing.

#### **Qualifications for Trustee Nominees**

The Committee requires that Trustee candidates have a college degree or equivalent business experience. The Committee may take into account a wide variety of factors in considering Trustee candidates, including (but not limited to): (i) availability and commitment of a candidate to attend meetings and perform his or her responsibilities on the Board, (ii) relevant industry and related experience, (iii) educational background, (iv) financial expertise, (v) an assessment of the candidate's ability, judgment and expertise and (v) overall diversity of the Board's composition.

#### **Identification of Nominees**

In identifying potential nominees for the Board, the Committee may consider candidates recommended by one or more of the following sources: (i) the Trust's current Trustees, (ii) the Trust's officers, (iii) the Trust's investment adviser(s), (iv) the Trust's shareholders (see below) and (v) any other source the Committee deems to be appropriate. The Committee may, but is not required to, retain a third party search firm at the expense of the Trust to identify potential candidates. The Committee will not nominate a person for election to the Board as a Trustee (unless such person is an "interested person," as defined by the Investment Company Act of 1940) after such person has reached the age of seventy-two (72).

#### **Consideration of Candidates Recommended By Shareholders**

The Committee will consider and evaluate nominee candidates properly submitted by shareholders on the same basis as it considers and evaluates candidates recommended by other sources. <u>Appendix B</u> to this Charter, as it may be amended from time to time by the Committee, sets forth procedures that must be followed by shareholders to properly submit a nominee candidate to the Committee (recommendations not properly submitted in accordance with <u>Appendix B</u> will not be considered by the Committee).

<sup>1</sup> As contemplated by certain rules under the Investment Company Act of 1940, as amended, the selection and nomination of candidates for election as members of the Board who are not Interested Persons shall be made by the incumbent members of the Board who are not Interested

B-1

#### Appendix A

Dreman/Claymore Dividend & Income Fund

Fiduciary/Claymore Dynamic Equity Fund

Fiduciary/Claymore MLP Opportunity Fund

Madison/Claymore Covered Call Fund

Old Mutual/Claymore Long-Short Fund

TS&W/Claymore Tax-Advantaged Balanced Fund

Claymore Exchange-Traded Fund Trust

Claymore Exchange-Traded Fund Trust 2

Claymore/Guggenheim Strategic Opportunities Fund

B-2

#### Appendix B

#### Procedures for Shareholders to Submit Nominee Candidates

A Trust shareholder must follow the following procedures in order to properly submit a nominee recommendation for the Committee's consideration.

1. The shareholder must submit any such recommendation (a "Shareholder Recommendation") in writing to the Trust, to the attention of the Secretary, at the Address of the principal executive offices of the Trust.

2. The Shareholder Recommendation must be delivered to or mailed and received at the principal executive offices of the Trust not less than one hundred and twenty (120) calendar days nor more than one hundred and fifty (150) calendar days prior to the date of the Board or shareholder meeting at which the nominee would be elected.

3. The Shareholder Recommendation must include: (i) a statement in writing setting forth (A) the name, age, date of birth, business address, residence address and citizenship of the person recommended by the shareholder (the "candidate"); (B) the class or series and number of all shares of the Trust owned of record or beneficially by the candidate, as reported to such shareholder by the candidate; (C) any other information regarding the candidate called for with respect to director nominees by paragraphs (a), (d), (e), (f) of Item 401 of Regulation S-K or paragraph (b) of Item 22 of Rule 14a-101 (Schedule 14A) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), adopted by the Securities and Exchange Commission (or the corresponding provisions of any regulation or rule subsequently adopted by the Securities and Exchange Commission or any successor agency applicable to the Trust); (D) any other information regarding the candidate that would be required to be disclosed if the candidate were a nominee in a proxy statement or other filing required to be made in connection with solicitation of proxies for election of Trustees or directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder; and (E) whether the recommending shareholder believes that the candidate is or will be an "interested person" of the Trust (as defined in the Investment Company Act of 1940, as amended) and, if not an "interested person," information regarding the candidate that will be sufficient for the Trust to make such determination; (ii) the written and signed consent of the candidate to be named as a nominee and to serve as a Trustee if elected; (iii) the recommending shareholder's name as it appears on the Trust's books; (iv) the class or series and number of all shares of the Trust owned beneficially and of record by the recommending shareholder; and (v) a description of all arrangements or understandings between the recommending shareholder and the candidate and any other persons (including their names) pursuant to which the recommendation is being made by the recommending shareholder. In addition, the Committee may require the candidate to furnish such other information as it may reasonably require or deem necessary to determine the eligibility of such candidate to serve on the Board.



PROXY TABULATOR P.O. BOX 9112 FARMINGDALE, NY 11735

# CLAYMORE/GUGGENHEIM STRATEGIC OPPORTUNITIES FUND

To vote by Mail

1) Read the Proxy Statement.

2) Check the appropriate boxes on the proxy card below.

3) Sign and date the proxy card.

4) Return the proxy card in the envelope provided.

TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS:

CLYRJ1 KEEP THIS PORTION FOR YOUR RECORDS

DETACH AND RETURN THIS PORTION ONLY

## THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED.

|            |                        |   |         | T            |             |   |
|------------|------------------------|---|---------|--------------|-------------|---|
|            | CLAYN                  | IORE/GUGGENHEIM STRATEGIC                 |         |              |             |   |
|            | OPPOR                  | TUNITIES FUND                             |         |              |             |   |
|            |                        |   |         |              |             |   |
|            |                        |   | For     | Withhold     | For All     | To withhold authority to vote<br>for any individual |
|            |                        |   | All     | All          | Except      | nominee(s), mark For All<br>Except and write the    |
| 1.         | To elect<br>serve      | two Trustees as Class II Trustees to      |         |              |             | number(s) of the nominee(s) on<br>the line below.   |
|            | until the<br>until the | Fund's 2010 annual meeting or<br>ir       |         |              |             |   |
|            | successo               | rs shall have been elected and qualified. | 0       | 0            | 0           |   |
|            |                        |   |         |              |             |   |
|            | Class II               | Nominees:                                 |         |              |             |   |
|            |                        | 5   |         |              |             |   |
|            | 01)                    | Ronald A. Nyberg                          |         |              |             |   |
|            | 02)                    | Ronald E. Toupin, Jr.                     |         |              |             |   |
|            |                        |   |         |              |             |   |
|            |                        |   |         |              |             |   |
| 2.         | To trans               | act such other business as may properly o | ome bef | ore the Annu | al Meeting  | or any adjournments or postponements thereof.       |
| <i>~</i> • | 10 transe              | aet suen outer business as may property e |         |              |             | of any adjournments of postponements dieleor.       |
|            |                        |   |         |              |             |   |
|            |                        |   |         |              |             |   |
|            |                        |   |         |              |             |   |
|            | Please r               | nark, date, sign & return the proxy       | promp   | otly in the  | enclosed en | nvelope.  |

| each holder should sign. W            | When signing as a | in attorney, | executor, | administrator, | ate. If the shares are held joint trustee, guardian, officer of he full title under signature( | a        |            |  |
|---------------------------------------|-------------------|--------------|-----------|----------------|--|----------|------------|--|
|                                       |                   |              |           |                |  |          |            |  |
|                                       |                   |              |           |                |  |          |            |  |
|                                       |                   |              |           |                |  |          |            |  |
|                                       |                   |              |           |                |  |          |            |  |
|                                       |                   |              |           |                |  |          |            |  |
|                                       |                   | -            |           |                |  | <b>a</b> | <b>D</b> . |  |
| Signature [PLEASE SIGN<br>WITHIN BOX] | Date              |              |           |                | Signature (Joint   | Owners)  | Date       |  |

| Solicited on behalf of the Board of Trustees  |
|---|
| CLAYMORE/GUGGENHEIM STRATEGIC OPPORTUNITIES   |
| FUND  |
| Annual Meeting of Shareholders  |
| October 22, 2008  |
|   |
|   |
| The annual meeting of shareholders of Claymore/Guggenheim Strategic Opportunities           |
| Fund (the Fund ) will be held at the offices of the Fund, 2455 Corporate West Drive, Lisle, |
| Illinois, 60532, on Wednesday, October 22, 2008, at 11:30 a.m., Central time (the Annual    |
| Meeting ). The undersigned hereby appoints each of Mark E. Mathiasen and Melissa J.         |
| Nguyen, and each of them or their respective designees, with full power of substitution and |
| revocation, as proxies to represent and to vote all shares of the undersigned at the Annual |
| Meeting and all adjournments thereof, with all powers the undersigned would possess if      |
|   |

| <br>personally present, upon the matters specified on the reverse side.  |  |
|--|--|
| SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED. IF<br>NO DIRECTION IS INDICATED AS TO THE PROPOSAL, THE PROXY SHALL<br>VOTE FOR SUCH PROPOSAL. THE PROXY MAY VOTE AT THEIR<br>DISCRETION ON ANY OTHER MATTER THAT MAY PROPERLY COME<br>BEFORE THE MEETING. |  |
| <br>PLEASE SIGN AND DATE ON THE REVERSE SIDE   |  |
|  |  |
|  |  |